Senti Biosciences, Inc.
SNTI Healthcare Biotechnology
Senti Biosciences, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $22,000.00, down 99.1% from fiscal 2023. In the quarter to June 2026, revenue fell 98.7%, EPS grew 26.8% and free cash flow fell 7.48%, each against the same quarter a year earlier.
Follow SNTI
A Balance Sheet is a financial statement that provides a snapshot of a company's assets, liabilities, and shareholders' equity at a specific point in time. It follows the formula: Assets = Liabilities + Shareholders' Equity. Key components include current and non-current assets, current and long-term liabilities, and equity. The Balance Sheet helps businesses and investors evaluate financial stability, liquidity, and capital structure. It's essential for assessing the company's ability to meet its obligations and fund future operations.
| Dec '21 | Dec '22 | Dec '23 | Dec '24 | Dec '25 | |
|---|---|---|---|---|---|
Cash and Short Term Investments |
56.03 | 98.56 | 35.93 | 48.28 | 16.42 |
Receivables |
0.48 | 0.63 | 17.70 | 1.81 | 1.60 |
Total current assets |
60.19 | 102.58 | 71.20 | 58.96 | 23.27 |
Property, Plant, Equpment (Net) |
12.37 | 51.36 | 25.34 | 21.29 | 12.89 |
Long-term receivables |
— | — | 1.12 | — | — |
Long-term assets (Other) |
3.43 | 3.65 | 5.55 | 3.64 | 3.55 |
Total non-current assets |
36.51 | 78.21 | 48.28 | 38.88 | 27.95 |
Total Assets |
96.70 | 180.79 | 119.48 | 97.84 | 51.22 |
Accounts Payable |
5.19 | 1.37 | 1.25 | 1.45 | 2.94 |
Accrued Expenses |
5.33 | 12.58 | 5.93 | 6.39 | 5.35 |
Current Part of Debt |
0.63 | 0.14 | 0.14 | 0.01 | — |
Current Part of Capital Lease |
— | — | 0.10 | 0.10 | — |
Current Revenue (Deferred) |
1.66 | 0.80 | 0.99 | 0.66 | 0.35 |
Total current liabilities |
14.54 | 18.05 | 12.67 | 13.15 | 13.97 |
Non-current Revenue (Deferred) |
0.18 | — | — | — | — |
Liabilities (Preferred Stock) |
171.83 | — | — | 25.11 | — |
Non-current Liabilities (Other) |
0.62 | 0.37 | 6.36 | 5.05 | 8.10 |
Total non-current liabilities |
193.62 | 35.48 | 39.90 | 59.05 | 31.66 |
Total liabilities |
208.16 | 53.53 | 52.57 | 72.19 | 45.63 |
Additional Paid In Capital |
3.62 | 300.54 | 311.26 | 322.78 | 364.16 |
Common Stock (Net) |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Retained Earnings |
(115.08) | (173.29) | (244.34) | (297.13) | (358.57) |
Common Equity (Total) |
(111.46) | 127.26 | 66.91 | 25.65 | 5.59 |
Shareholders Equity (Total) |
(111.46) | 127.26 | 66.91 | 25.65 | 5.59 |
Shareholders Equity and Liabilities (Total) |
96.70 | 180.79 | 119.48 | 97.84 | 51.22 |
Shares (Common) |
0.30 | 4.41 | 4.57 | 4.83 | 30.88 |
Shareholders Equity (Tangible) |
(111.46) | 127.26 | 66.91 | 25.65 | 5.59 |
Net Debt |
(55.41) | (98.43) | (35.79) | (48.27) | (16.42) |
Total Debt |
0.63 | 0.14 | 0.14 | 0.01 | — |